Pfizer is in-licensing a bispecific antibody drug for cancer that China-based 3SBio designed to block the proteins PD-1 and VEGF. The deal puts the pharmaceutical giant in a growing group of companies developing bispecific antibodies for those targets, many of them with molecules originally developed in China.
Pfizer said a patient dosed with danuglipron developed potential drug-induced liver injury. Pfizer is stopping further work on this program, a move that comes nearly two years after it discontinued development of a different obesity drug due to liver safety signals in a clinical trial.
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million. Meanwhile, Pfizer continued the culling of its gene therapies with the discontinuation of Beqvez for hemophilia B.
Pfizer’s Braftovi received accelerated FDA approval in December as a first-line treatment for metastatic colorectal cancer with a particular genetic mutation. The pharma giant now says the drug has hit primary and secondary goals of its Phase 3 clinical trial.
Many healthcare executives are applauding the list of additional drugs chosen for the Medicare Drug Price Negotiation Program, while some drug companies are opposing it.
Albert Bourla and other healthcare CEOs talked about the efficacy of vaccines and how public health could take a big turn for the worse if the incoming Trump administration veered away from accepted norms regarding vaccines.
Employees who enjoy their benefits are more inclined to stay with their company. A 2025 Marsh McLennan Agency report said 73% of employees would remain if plan options were better.
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program.
BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.
GoodRx announced a new e-commerce solution starting with over-the-counter birth control pill Opill. It also is offering new affordability programs for menopause medications with Pfizer.
To address the complicated healthcare landscape in the U.S., Pfizer launched a new direct-to-consumer virtual service called PfizerForAll. It follows Eli Lilly, which launched a similar product in January.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Despite achieving strong responses against influenza A, a Phase 3 test of a Pfizer and BioNTech flu and Covid-19 combination vaccine did not meet goals against less common influenza B. These results come two months after Moderna’s combination vaccine succeeded in its Phase 3 trial.
Here is a selection of recent executive hires, retirements, promotions and layoffs occurring across the healthcare industry.
Pfizer’s hemophilia A gene therapy reduced annualized bleeding rates in a Phase 3 clinical trial, setting the stage for discussions with regulators. However, the market for such one-time treatments is uncertain, as uptake of commercialized hemophilia gene therapies remains slow.
A Pfizer gene therapy for Duchenne muscular dystrophy failed its Phase 3 clinical trial. But analysts draw distinctions between that therapy and Sarepta Therapeutics’ Elevidys, which awaits an FDA decision that could grant it full regulatory approval.
The FDA has approved Beqvez, a Pfizer gene therapy developed for moderate-to-severe hemophilia B. The one-time treatment carries a $3.5 million price tag, the same as a CSL Behring gene therapy already available for treating the inherited bleeding disorder.